- Home
- ADGM vs CING Comparison
ADGM vs CING Comparison
Compare ADGM & CING Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADGM
- CING
- Stock Information
- Founded
- ADGM 2011
- CING 2012
- Country
- ADGM United States
- CING United States
- Employees
- ADGM N/A
- CING N/A
- Industry
- ADGM
- CING Biotechnology: Pharmaceutical Preparations
- Sector
- ADGM
- CING Health Care
- Exchange
- ADGM NYSE
- CING Nasdaq
- Market Cap
- ADGM 12.7M
- CING 14.4M
- IPO Year
- ADGM N/A
- CING 2021
- Fundamental
- Price
- ADGM $1.40
- CING $4.27
- Analyst Decision
- ADGM
- CING Strong Buy
- Analyst Count
- ADGM 0
- CING 3
- Target Price
- ADGM N/A
- CING $16.00
- AVG Volume (30 Days)
- ADGM 209.5K
- CING 118.1K
- Earning Date
- ADGM 03-04-2025
- CING 03-31-2025
- Dividend Yield
- ADGM N/A
- CING N/A
- EPS Growth
- ADGM N/A
- CING N/A
- EPS
- ADGM N/A
- CING N/A
- Revenue
- ADGM $543,000.00
- CING N/A
- Revenue This Year
- ADGM N/A
- CING N/A
- Revenue Next Year
- ADGM N/A
- CING N/A
- P/E Ratio
- ADGM N/A
- CING N/A
- Revenue Growth
- ADGM 187.30
- CING N/A
- 52 Week Low
- ADGM $0.75
- CING $1.80
- 52 Week High
- ADGM $9.34
- CING $20.83
- Technical
- Relative Strength Index (RSI)
- ADGM N/A
- CING 42.05
- Support Level
- ADGM N/A
- CING $4.22
- Resistance Level
- ADGM N/A
- CING $4.58
- Average True Range (ATR)
- ADGM 0.00
- CING 0.32
- MACD
- ADGM 0.00
- CING -0.04
- Stochastic Oscillator
- ADGM 0.00
- CING 12.64
About ADGM ADAGIO MEDICAL HOLDINGS INC
Adagio Medical Holdings Inc is an innovator in catheter ablation technologies for treatment of cardiac arrhythmias. The company focuses on developing innovative cryoablation technologies that create contiguous, transmural lesions to treat cardiac arrhythmias, including paroxysmal and persistent atrial fibrillation, atrial flutter, and ventricular tachycardia.
About CING Cingulate Inc.
Cingulate Inc is a clinical-stage biopharmaceutical company utilizing its proprietary precision timed-release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic areas to use PTR technology to develop future product candidates.